Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
The Medicines Company stock logo
MDCO
Medicines
$84.90
$84.90
$17.81
$84.98
$6.77B1.19.55 million shsN/A
Pfizer Inc. stock logo
PFE
Pfizer
$25.25
-0.3%
$23.62
$20.92
$31.54
$143.48B0.5845.98 million shs5.41 million shs
Banco Santander, S.A. stock logo
SAN
Banco Santander
$8.50
+0.4%
$7.80
$4.27
$8.52
$128.72B0.995.62 million shs1.66 million shs
Sanofi stock logo
SNY
Sanofi
$48.31
-2.0%
$50.77
$45.80
$60.12
$118.56B0.482.33 million shs237,235 shs
Sanofi stock logo
SNYNF
Sanofi
$96.65
+0.1%
$101.68
$91.81
$122.03
N/AN/A21,440 shs1,113 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
The Medicines Company stock logo
MDCO
Medicines
0.00%0.00%0.00%0.00%0.00%
Pfizer Inc. stock logo
PFE
Pfizer
+1.16%+4.24%+8.00%+4.22%-9.02%
Banco Santander, S.A. stock logo
SAN
Banco Santander
+2.42%+5.09%+5.42%+28.87%+82.33%
Sanofi stock logo
SNY
Sanofi
+0.53%+3.16%+0.24%-9.72%+1.59%
Sanofi stock logo
SNYNF
Sanofi
+0.11%+2.57%+0.04%-12.01%+1.26%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
The Medicines Company stock logo
MDCO
Medicines
N/AN/AN/AN/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
4.853 of 5 stars
2.33.04.24.32.21.73.1
Banco Santander, S.A. stock logo
SAN
Banco Santander
4.1382 of 5 stars
0.05.02.52.81.90.03.8
Sanofi stock logo
SNY
Sanofi
4.2752 of 5 stars
3.64.02.50.02.00.03.1
Sanofi stock logo
SNYNF
Sanofi
0.9035 of 5 stars
0.02.01.74.01.90.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
The Medicines Company stock logo
MDCO
Medicines
0.00
N/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
2.53
Moderate Buy$29.1715.53% Upside
Banco Santander, S.A. stock logo
SAN
Banco Santander
3.00
BuyN/AN/A
Sanofi stock logo
SNY
Sanofi
3.11
Buy$61.5027.30% Upside
Sanofi stock logo
SNYNF
Sanofi
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PFE, SNY, SNYNF, SAN, and MDCO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/2/2025
Sanofi stock logo
SNY
Sanofi
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
6/4/2025
Banco Santander, S.A. stock logo
SAN
Banco Santander
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
6/3/2025
Sanofi stock logo
SNY
Sanofi
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
6/2/2025
Sanofi stock logo
SNY
Sanofi
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$56.00
4/30/2025
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$24.00 ➝ $25.00
4/28/2025
Sanofi stock logo
SNY
Sanofi
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/22/2025
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight ➝ Neutral$24.00
4/15/2025
Sanofi stock logo
SNY
Sanofi
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$65.00
4/8/2025
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$28.00 ➝ $24.00
4/8/2025
Pfizer Inc. stock logo
PFE
Pfizer
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$32.00 ➝ $25.00
(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
The Medicines Company stock logo
MDCO
Medicines
$6.14M1,102.36N/AN/A($0.30) per share-283.00
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B2.26$4.40 per share5.74$15.62 per share1.62
Banco Santander, S.A. stock logo
SAN
Banco Santander
$66.96B1.92$1.11 per share7.62$7.34 per share1.16
Sanofi stock logo
SNY
Sanofi
$44.46B2.67$5.25 per share9.20$33.20 per share1.46
Sanofi stock logo
SNYNF
Sanofi
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
The Medicines Company stock logo
MDCO
Medicines
-$123.16M-$2.91N/AN/AN/AN/AN/A-25.70%N/A
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.3818.298.330.9112.62%20.33%8.53%8/5/2025 (Estimated)
Banco Santander, S.A. stock logo
SAN
Banco Santander
$13.61B$0.879.769.230.8916.92%12.26%0.72%7/23/2025 (Estimated)
Sanofi stock logo
SNY
Sanofi
$6.02B$2.8017.2710.171.0114.56%17.15%9.80%7/24/2025 (Estimated)
Sanofi stock logo
SNYNF
Sanofi
N/A$3.0831.33N/AN/AN/AN/A7/31/2025 (Estimated)

Latest PFE, SNY, SNYNF, SAN, and MDCO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/24/2025Q2 2025
Sanofi stock logo
SNY
Sanofi
$0.98N/AN/AN/AN/AN/A
7/23/2025Q2 2025
Banco Santander, S.A. stock logo
SAN
Banco Santander
$0.27N/AN/AN/AN/AN/A
4/30/2025Q1 2025
Banco Santander, S.A. stock logo
SAN
Banco Santander
$0.22$0.22N/A$0.22$15.94 billion$17.69 billion
4/29/2025Q1 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.67$0.92+$0.25$0.52$14.43 billion$13.72 billion
4/24/2025Q1 2025
Sanofi stock logo
SNY
Sanofi
$0.90$0.94+$0.04$0.80$9.79 billion$10.41 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
The Medicines Company stock logo
MDCO
Medicines
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.81%N/A124.64%16 Years
Banco Santander, S.A. stock logo
SAN
Banco Santander
$0.182.12%N/A20.69%N/A
Sanofi stock logo
SNY
Sanofi
$1.603.31%N/A57.14%N/A
Sanofi stock logo
SNYNF
Sanofi
$2.802.90%N/A90.78%N/A

Latest PFE, SNY, SNYNF, SAN, and MDCO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/25/2025
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.08%7/25/20257/25/20259/2/2025
4/23/2025
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.69%5/9/20255/9/20256/13/2025
4/15/2025
Sanofi stock logo
SNY
Sanofi
annual$2.03693.1%5/9/20255/9/20256/12/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
The Medicines Company stock logo
MDCO
Medicines
21.45
0.77
0.77
Pfizer Inc. stock logo
PFE
Pfizer
0.64
1.26
0.96
Banco Santander, S.A. stock logo
SAN
Banco Santander
N/A
0.25
0.25
Sanofi stock logo
SNY
Sanofi
0.16
1.37
0.69
Sanofi stock logo
SNYNF
Sanofi
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
The Medicines Company stock logo
MDCO
Medicines
N/A
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Banco Santander, S.A. stock logo
SAN
Banco Santander
9.19%
Sanofi stock logo
SNY
Sanofi
14.04%
Sanofi stock logo
SNYNF
Sanofi
30.06%

Insider Ownership

CompanyInsider Ownership
The Medicines Company stock logo
MDCO
Medicines
8.41%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
Banco Santander, S.A. stock logo
SAN
Banco Santander
9.48%
Sanofi stock logo
SNY
Sanofi
1.00%
Sanofi stock logo
SNYNF
Sanofi
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
The Medicines Company stock logo
MDCO
Medicines
6279.72 millionN/AOptionable
Pfizer Inc. stock logo
PFE
Pfizer
81,0005.69 billion5.68 billionOptionable
Banco Santander, S.A. stock logo
SAN
Banco Santander
199,95815.15 billion13.72 billionOptionable
Sanofi stock logo
SNY
Sanofi
82,8782.45 billion2.43 billionOptionable
Sanofi stock logo
SNYNF
Sanofi
91,600N/AN/ANot Optionable

Recent News About These Companies

Sanofi (SAN.PA)
Sanofi (SNYNF) Gets a Buy from Berenberg Bank
Guggenheim Reaffirms Their Buy Rating on Sanofi (SNYNF)
Sanofi (SNYNF) Gets a Hold from Deutsche Bank
J.P. Morgan Keeps Their Hold Rating on Sanofi (SNYNF)
Goldman Sachs Reaffirms Their Hold Rating on Sanofi (SNYNF)
Barclays Keeps Their Buy Rating on Sanofi (SNYNF)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Medicines stock logo

Medicines NASDAQ:MDCO

The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey.

Pfizer stock logo

Pfizer NYSE:PFE

$25.25 -0.07 (-0.29%)
As of 10:21 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Banco Santander stock logo

Banco Santander NYSE:SAN

$8.49 +0.04 (+0.41%)
As of 10:21 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Banco Santander, S.A. provides various financial services worldwide. The company operates through Retail Banking, Santander Corporate & Investment Banking, Wealth Management & Insurance, and PagoNxt segments. It offers demand and time deposits, mutual funds, and current and savings accounts; mortgages, consumer finance, loans, and various financing solutions; and project finance, debt capital markets, global transaction banking, and corporate finance services. The company also provides asset management and private banking services; and insurance products. In addition, it offers corporate and investment banking services; and digital payment solutions. Further, it offers online banking and financial services to retail, business, institutional, corporate, private banking and university customers and clients. The company was formerly known as Banco Santander Central Hispano SA and changed its name to Banco Santander, S.A. in February 2007. Banco Santander, S.A. was founded in 1856 and is headquartered in Madrid, Spain.

Sanofi stock logo

Sanofi NASDAQ:SNY

$48.31 -1.00 (-2.02%)
As of 10:21 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Sanofi stock logo

Sanofi OTCMKTS:SNYNF

$96.65 +0.11 (+0.11%)
As of 07/2/2025 03:12 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.